nach oben

Erschienen in:

01.03.2014 | Original Paper

Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation

verfasst von: Anastasia Spyropoulou, Antonios Gargalionis, Georgia Dalagiorgou, Christos Adamopoulos, Kostas A. Papavassiliou, Robert William Lea, Christina Piperi, Athanasios G. Papavassiliou

Erschienen in: NeuroMolecular Medicine | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Posttranslational modifications of histones are considered as critical regulators of gene expression, playing significant role in the pathogenesis and progression of tumors. Trimethylation of histone 3 lysine 9 (H3K9me3), a repressed transcription mark, is mainly regulated by the histone lysine N-methyltransferases (HKMTs), SUV39H1 and SETDB1. The present study investigated the implication of these HKMTs in glioma progression. SUV39H1 and SETDB1 expression was upregulated in glioma cell lines (GOS-3, 1321N1, T98G, U87MG) and in glioma tissues compared to normal brain being positively correlated with grade and histological malignancy. Suppression by siRNA of the two HKMTs for 24 and 48 h resulted in significantly reduced proliferation of GOS-3 and T98G glioma cells with siSUV39H1 effects been most prominent. Furthermore, HKMTs knockdown-induced apoptosis with a high rate of apoptotic cells have been observed after siSUV39H1 and siSETDB1 for both cell lines. Additionally, suppression of the two HKMTs reduced cell migration and clonogenic ability of both glioma cell lines. Our results indicate overexpression of SETDB1 and SUV39H1 in gliomas. Treatments that alter HKMT expression affect the proliferative and apoptotic rates in glioma cells as well as their migratory and colony formation capacity. These data suggest that both HKMTs and especially SUV39H1 may serve as novel biomarkers for future therapeutic targeting of these tumors.

Aagaard, L., Schmid, M., Warburton, P., & Jenuwein, T. (2000). Mitotic phosphorylation of SUV39H1, a novel component of active centromeres, coincides with transient accumulation at mammalian centromeres. Journal of Cell Science, 113, 817–829.PubMed

Alimova, I., Venkataraman, S., Harris, P., Marquez, V. E., Northcott, P. A., Dubuc, A., et al. (2012). Targeting the enhancer of zeste homologue 2 in medulloblastoma. International Journal of Cancer, 131, 1800–1809.CrossRef

Ayyanathan, K., Lechner, M. S., Bell, P., Maul, G. G., Schultz, D. C., Yamada, Y., et al. (2003). Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: A mammalian cell culture model of gene variegation. Genes & Development, 17, 1855–1869.CrossRef

Babbio, F., Pistore, C., Curti, L., Castiglioni, I., Kunderfranco, P., Brino, L., et al. (2012). The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene, 31, 4878–4887.CrossRefPubMed

Baumgart, S., Glesel, E., Singh, G., Chen, N. M., Reutlinger, K., Zhang, J., et al. (2012). Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology, 142, 388–398.CrossRefPubMedCentralPubMed

Bennani-Baiti, I. M. (2011). Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis. Epigenomics, 3, 715–732.CrossRefPubMed

Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003). EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. The EMBO journal, 22, 5323–5335.CrossRefPubMed

Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H., Schlegelberger, B., et al. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 436, 660–665.CrossRefPubMed

Carbone, R., Botrugno, O. A., Ronzoni, S., Insinga, A., Di Croce, L., Pelicci, P. G., et al. (2006). Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Molecular and Cellular Biology, 26, 1288–1296.CrossRefPubMedCentralPubMed

Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., et al. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature, 471, 513–517.CrossRefPubMedCentralPubMed

Chaib, H., Nebbioso, A., Prebet, T., Castellano, R., Garbit, S., Restouin, A., et al. (2012). Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia, 26, 662–674.CrossRefPubMed

Chernov, A. V., Sounni, N. E., Remacle, A. G., & Strongin, A. Y. (2009). Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. The Journal of Biological Chemistry, 284, 12727–12734.CrossRefPubMed

Collett, K., Eide, G. E., Arnes, J., Stefansson, I. M., Eide, J., Braaten, A., et al. (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research, 12, 1168–1174.CrossRefPubMed

Dong, C., Wu, Y., Wang, Y., Wang, C., Kang, T., Rychahou, P. G., et al. (2013). Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene, 32, 1351–1362.CrossRefPubMedCentralPubMed

Fan, D. N., Tsang, F. H., Tam, A. H., Au, S. L., Wong, C. C., Wei, L., et al. (2013). Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology, 57, 637–647.CrossRefPubMed

Fanelli, M., Caprodossi, S., Ricci-Vitiani, L., Porcellini, A., Tomassoni-Ardori, F., Amatori, S., et al. (2008). Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene, 27, 358–365.CrossRefPubMed

Farmaki, E., Mkrtchian, S., Papazian, I., Papavassiliou, A. G., & Kiaris, H. (2011). ERp29 regulates response to doxorubicin by a PERK-mediated mechanism. Biochimica et Biophysica Acta, 1813, 1165–1171.CrossRefPubMed

Firestein, R., Cui, X., Huie, P., & Cleary, M. L. (2000). Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9. Molecular and Cellular Biology, 20, 4900–4909.CrossRefPubMedCentralPubMed

Horbinski, C. (2013). To BRAF or not to BRAF: Is that even a question anymore? Journal of Neuropathology and Experimental Neurology, 72, 2–7.CrossRefPubMedCentralPubMed

Hou, P., Liu, D., Dong, J., & Xing, M. (2012). The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle, 11, 286–295.CrossRefPubMed

Kang, M. Y., Lee, B. B., Kim, Y. H., Chang, D. K., Kyu Park, S., Chun, H. K., et al. (2007). Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer. International Journal of Cancer, 121, 2192–2197.CrossRef

Karpinski, P., Ramsey, D., Grzebieniak, Z., Sasiadek, M. M., & Blin, N. (2008). The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Molecular Cancer Research, 6, 585–591.CrossRefPubMed

Kassambara, A., Klein, B., & Moreaux, J. (2009). MMSET is overexpressed in cancers: Link with tumor aggressiveness. Biochemical and Biophysical Research Communications, 379, 840–845.CrossRefPubMed

Kim, H. A., Koo, B. K., Cho, J. H., Kim, Y. Y., Seong, J., Chang, H. J., et al. (2012). Notch1 counteracts WNT/beta-catenin signaling through chromatin modification in colorectal cancer. The Journal of Clinical Investigation, 122, 3248–3259.CrossRefPubMedCentralPubMed

Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 11606–11611.CrossRefPubMedCentralPubMed

Kondo, Y., Shen, L., Ahmed, S., Boumber, Y., Sekido, Y., Haddad, B. R., et al. (2008). Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One, 3, e2037.CrossRefPubMedCentralPubMed

Kreth, S., Thon, N., Eigenbrod, S., Lutz, J., Ledderose, C., Egensperger, R., et al. (2011). O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One, 6, e17156.CrossRefPubMedCentralPubMed

Lakshmikuttyamma, A., Scott, S. A., DeCoteau, J. F., & Geyer, C. R. (2010). Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene, 29, 576–588.CrossRefPubMed

Lee, C. H., Hung, H. W., Hung, P. H., & Shieh, Y. S. (2010). Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Molecular cancer, 9, 64.CrossRefPubMedCentralPubMed

Lee, J., Son, M. J., Woolard, K., Donin, N. M., Li, A., Cheng, C. H., et al. (2008). Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell, 13, 69–80.CrossRefPubMedCentralPubMed

Li, H., Rauch, T., Chen, Z. X., Szabo, P. E., Riggs, A. D., & Pfeifer, G. P. (2006). The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. The Journal of Biological Chemistry, 281, 19489–19500.CrossRefPubMed

Lindgren, D., Sjodahl, G., Lauss, M., Staaf, J., Chebil, G., Lovgren, K., et al. (2012). Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One, 7, e38863.CrossRefPubMedCentralPubMed

Loenarz, C., & Schofield, C. J. (2008). Expanding chemical biology of 2-oxoglutarate oxygenases. Nature Chemical Biology, 4, 152–156.CrossRefPubMed

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., et al. (2012). IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 483, 474–478.CrossRefPubMedCentralPubMed

Macgregor, S., Montgomery, G. W., Liu, J. Z., Zhao, Z. Z., Henders, A. K., Stark, M., et al. (2011). Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 43, 1114–1118.CrossRefPubMedCentralPubMed

Martin, C., & Zhang, Y. (2005). The diverse functions of histone lysine methylation. Nature Reviews Molecular Cell Biology, 6, 838–849.CrossRefPubMed

Northcott, P. A., Nakahara, Y., Wu, X., Feuk, L., Ellison, D. W., Croul, S., et al. (2009). Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature Genetics, 41, 465–472.CrossRefPubMed

Orzan, F., Pellegatta, S., Poliani, P. L., Pisati, F., Caldera, V., Menghi, F., et al. (2011). Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathology and Applied Neurobiology, 37, 381–394.CrossRefPubMed

Patani, N., Jiang, W. G., Newbold, R. F., & Mokbel, K. (2011). Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Research, 31, 4115–4125.PubMed

Peters, A. H., O’Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schofer, C., et al. (2001). Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell, 107, 323–337.CrossRefPubMed

Piperi, C., Themistocleous, M. S., Papavassiliou, G. A., Farmaki, E., Levidou, G., Korkolopoulou, P., et al. (2010). High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: Association with histopathological characteristics, inflammatory mediators and clinical outcome. Molecular Medicine, 16, 1–9.CrossRefPubMedCentralPubMed

Pogribny, I. P., Ross, S. A., Tryndyak, V. P., Pogribna, M., Poirier, L. A., & Karpinets, T. V. (2006). Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis, 27, 1180–1186.CrossRefPubMed

Portela, A., & Esteller, M. (2010). Epigenetic modifications and human disease. Nature Biotechnology, 28, 1057–1068.CrossRefPubMed

Rai, K., Nadauld, L. D., Chidester, S., Manos, E. J., James, S. R., Karpf, A. R., et al. (2006). Zebra fish Dnmt1 and Suv39h1 regulate organ-specific terminal differentiation during development. Molecular and Cellular Biology, 26, 7077–7085.CrossRefPubMedCentralPubMed

Rea, S., Eisenhaber, F., O’Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature, 406, 593–599.CrossRefPubMed

Sarraf, S. A., & Stancheva, I. (2004). Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Molecular Cell, 15, 595–605.CrossRefPubMed

Schultz, D. C., Ayyanathan, K., Negorev, D., Maul, G. G., & Rauscher, F. J, 3rd. (2002). SETDB1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes & Development, 16, 919–932.CrossRef

Spyropoulou, A., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2013). Deregulated chromatin remodeling in the pathobiology of brain tumors. NeuroMolecular Medicine, 15, 1–24.CrossRefPubMed

Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., et al. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 479–483.CrossRefPubMedCentralPubMed

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624–629.CrossRefPubMed

Venneti, S., Felicella, M. M., Coyne, T., Phillips, J. J., Gorovets, D., Huse, J. T., et al. (2013). Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. Journal of Neuropathology and Experimental Neurology, 72, 298–306.CrossRefPubMed

Wang, G. G., Allis, C. D., & Chi, P. (2007). Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling. Trends in Molecular Medicine, 13, 373–380.CrossRefPubMed

Wang, H., An, W., Cao, R., Xia, L., Erdjument-Bromage, H., Chatton, B., et al. (2003). mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Molecular Cell, 12, 475–487.CrossRefPubMed

Watanabe, H., Soejima, K., Yasuda, H., Kawada, I., Nakachi, I., Yoda, S., et al. (2008). Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell International, 8, 15.CrossRefPubMedCentralPubMed

Weikert, S., Christoph, F., Kollermann, J., Muller, M., Schrader, M., Miller, K., et al. (2005). Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. International Journal of Molecular Medicine, 16, 349–353.PubMed

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360, 765–773.CrossRefPubMedCentralPubMed

Titel: Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation
verfasst von: Anastasia Spyropoulou
Antonios Gargalionis
Georgia Dalagiorgou
Christos Adamopoulos
Kostas A. Papavassiliou
Robert William Lea
Christina Piperi
Athanasios G. Papavassiliou
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 1/2014
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-013-8254-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Interleukin-1β Promotes Long-Term Potentiation in Patients with Multiple Sclerosis

Glial Uptake of Amyloid Beta Induces NLRP3 Inflammasome Formation via Cathepsin-Dependent Degradation of NLRP10

Curcumin Nanoparticles Attenuate Neurochemical and Neurobehavioral Deficits in Experimental Model of Huntington’s Disease

Erratum to: Twelve Novel Atm Mutations Identified in Chinese Ataxia Telangiectasia Patients

Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease